Cardiac Tissue 6,750,000 Vascular Tissue 7,600,000 Orthopaedic Tissue 40,000 BioGlue + Related 12,300,000 BioFoam 0 HemoStase 2,100,000 Other Medical Products 25,000 Other Product 240,000 Total Product Sales 29,055,000
I think CRY is going to have a fairly good first quarter. Here are my revenue estimates. Might as well have some fun guessing the numbers while we wait.
I'm guessing EPS of $0.09/share for the quarter. CRY should pop to around $7.25 at that time (May 15, 2010). If they come in less than $0.09/share, it is likely to be caused by Medafor issues.
Other comments: If the overall market were to go down 10%, CRY is going to get whacked roughly in line with the market generally. The Medafor/CRY problem is going to take time to resolve. The key revenue numbers to watch are the Bioglue sales and the Hemostase sales.
rroach, thank you for adding some good content to this message board.